“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
EU in a position to compensate ”certain ‘responsibilities’: EU official
When it comes to shooting, the EU goes behind the US, giving it a full shield
Eu has only concluded one vaccine agreement with AstraZeneca
By Francesco Guarascio
BRUSSELS, 26 August (Reuters) – The European Union is providing partial coverage to vaccine brands that oppose the legal dangers associated with the side effects of their possible COVID-19 injections, European officials said, to a extent that hinders agreements and contrasts with the US.U.S. politics.
Because vaccines evolve at record speed during the pandemic, there is a greater threat that they will have accidental or may not be effective consequences.The financial policy of these responsibilities is a key detail in discussions between drug brands and governments seeking vaccines in advance.
In these ordinary circumstances, EU governments “are in a position to financially cover some of the dangers of business,” an EU official told Reuters.However, the official added that strict EU liability regulations remained in place.
These regulations treat vaccine brands and other brands as culprits for their products sold in the EU, with the exception of rare cases in which, for example, they have been put into circulation.
The EU court increased the burden on drug brands in 2017 by ruling that vaccine users were entitled to reimbursement if a shot resulted in a negative effect, even in the absence of clinical consensus on the subject.
Reducing the legal burden on vaccine brands was a priority in the EU of the pandemic, as it is considered very important to convince drug brands to invest in dicy vaccines, according to an eu internal document dated 7 May and noticed through Reuters.
PROBLEM BLOCK
But donations to vaccine brands have not live up to their expectations.
EU officials concerned about confidential negotiations told Reuters in July that liability issues were among the obstacles in talks with US drug brands Johnson.
The EU later than negotiations with J
A spokesman for the European Commission declined to say that liability issues were an impediment in discussions with vaccine manufacturers.
The EU procurement agreement reached earlier in August on the possible COVID-19 vaccine developed through AstraZeneca and the University of Oxford, which is also the only agreement reached through Brussels, provides only partial liability coverage.
“The contract states that day-to-day work and money prices are shared between the parties,” the Belgian Medicines Agency said in an agreement reached through the Commission with AstraZeneca on behalf of the 27 EU states, adding Belgium.
“Advance purchase agreements offer member states to compensate the manufacturer for certain day-to-day jobs incurred,” a commission official said when asked about the deal. The official gave additional details.
The EU’s position on day-to-day work would possibly partly explain why, despite having a larger population than the US, it is falling behind Washington in obtaining possible vaccines opposed to COVID-19.
The U.S. formula completely transfers the vaccine tax to the government and protects drug manufacturers, as widespread inoculation against the disease is considered an advantage for society.
Congress has earmarked $30 billion this year to combat COVID-19, adding investments for vaccine progression and in all likelihood any mandatory compensation.
The EU equivalent to this is an emergency fund that took advantage of the pandemic and is expected to use around 2 billion euros ($2.4 billion) to help vaccine brands expand vaccines and fill their responsibilities, EU officials said.
(1 USD – 0.8465 euros)
(Report through Francesco Guarascio @fraguarascio; Edited through Mark Potter)